Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally?The Motley Fool • 01/30/26
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?Zacks Investment Research • 01/30/26
Exclusive: Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data showsReuters • 01/28/26
Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?Zacks Investment Research • 01/27/26
Oral Wegovy Is Off To An Astronomical Launch. Will It Save Novo Nordisk Stock?Investors Business Daily • 01/23/26
What obesity drugmakers see next in the market: More pills, easier access and drug combinationsCNBC • 01/23/26